<DOC>
	<DOCNO>NCT00998036</DOCNO>
	<brief_summary>This Phase I research study design determine maximum tolerate dos cisplatin , temsirolimus , erlotinib combination treatment triple negative breast cancer ( TNBC ) patient .</brief_summary>
	<brief_title>Study Temsirolimus , Erlotinib Cisplatin Solid Tumors</brief_title>
	<detailed_description>The stratification breast cancer patient treatment target either estrogen receptor ( ER ) HER2 receptor base upon measurement ER/PR HER2 tumor tissue revolutionize treatment breast cancer . However , success stratification result recognition effective rational treatment exist patient lack receptor . The term `` triple negative breast cancer '' ( TNBC ) coin define class unresponsive patient , base upon lack hormone receptor estrogen progesterone HER2 oncogene . TNBC thus represent form breast cancer target therapy know . Identifying understand signal pathways receptor contribute triple negative tumor growth therefore high priority order develop rational therapy analogous one already develop HER2 ER . TNBC heterogeneous regard molecular alteration prognosis actually encompass diverse form breast cancer ; hence , single therapeutic strategy likely effective . However , subclassification TNBC base upon identification distinct set molecular alteration identify basal like form disease poor prognosis enrichment distinct molecular characteristic think ripe target therapeutic intervention base clinical need improve molecular understanding . A phase I study combination erlotinib CCI779 ( temsirolimus ) glioblastoma patient report ASCO 2007 . The erlotinib dose fixed 150 mg maximum tolerate dose temsirolimus report likely 15 mg ( 1 6 patient grade 3 rash ) . Rash , diarrhea , mucositis encounter dose limit toxicity . Pharmacokinetics response data yet report . Therefore , goal maintain target inhibition ( mTOR EGFR ) minimize toxicity ( case , rash ) . This toxicity may explain part interaction erlotinib temsirolimus metabolism . Erlotinib show reduce clearance CYP450 3A4 substrate midazolam . Everolimus ( RAD001 ) temsirolimus CYP450 3A4 substrate . In Phase I trial , erlotinib increase systemic exposure everolimus , significantly high day 22 ( 476 ± 161 ng*hr/mL ) compare day 8 ( 393 ± 156 ng*hr/mL ; p = 0.020 ) . A phase I everolimus gefitinib also report , MTDs : everolimus 5 mg , gefitinib 250 mg. Two patient treat 10 mg dose level everolimus experience doselimiting grade 5 hypotension grade 3 stomatitis , respectively . Pharmacokinetics demonstrate significant interaction agent . Thus , Phase I trial , mTOR inhibitor EGFR inhibitor safely give together dos show inhibit respective target Phase II study ongoing advanced renal cell , pancreatic , glioma , breast ( specifically TNBC ) cancer . The rationale add cisplatin erlotinib mTOR inhibitor many . Cisplatin known active cytotoxic breast cancer . It non overlap toxicity erlotinib TORC1 mTOR inhibitor patient unlikely previously treat cisplatin . TNBC mutant p53 associate identified subset cisplatin sensitive cell line p53 mutation also associate PTEN loss EGFR overexpression . In , addition , synergistic interaction observe platinum agent carboplatin breast cancer cell line . Therefore , cytotoxic DNA damaging agent cisplatin could trigger apoptotic death cell whose PI3K survival pathway effectively inhibit mTOR inhibition erlotinib .</detailed_description>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Confirmed pathologic diagnosis solid tumor curable available therapy combination cisplatin , temsirolimus , erlotinib reasonable treatment . Patients measurable nonmeasurable disease eligible entry study . Tumor marker may consider nonmeasurable disease . Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . No chemotherapy radiotherapy may give within 3 week prior start protocol treatment . Patients must ≥18 year old . Performance Status : ECOG 01 ( define section 10.4 ) . Life expectancy great 12 week . Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Required Laboratory Values : ANC ≥1,500/mm3 , platelet ≥100,000/mm3 , hemoglobin ≥9.0 g/dL , total bilirubin ≤1.5 x ULN , AST/ALT ≤3.0 x ULN , alkaline phosphatase ≤2.5 x ULN , creatinine ≤2.0 x ULN OR Patients must either normal serum creatinine ( &lt; = IULN ) OR estimate creatinine clearance 60 ml/min ( CockcroftGault formula ) within 28 day prior registration . PT/INR ≤1.5 , unless patient full dose warfarin stable dose LMW heparin therapeutic INR &gt; 1.5 ≤3 . Patients triglyceride level &gt; 400 mg/dL start lipid lower agent reevaluate within 1 week . If level go ≤400 mg/dL , consider trial continue lipid lowering agent . Concomitant Medications : Temsirolimus Erlotinib primarily metabolize CYP3A4 . Patients CAN NOT receive enzymeinducing enzyme inhibit agent list : Inhibitors : Amiodarone , Amprenavir , Atazanavir , Chloramphenicol , Clarithromycin , Conivaptan , Cyclosporine , Darunavir , Dasatinib , Delavirdine , Diltiazem , Erythromycin , Fluconazole , Fluoxetine , Fluvoxamine , Fosamprenavir , Imatinib , Indinavir , Isoniazid , Itraconazole , Ketoconazole , Lapatinib , Miconazole , Nefazodone , Nelfinavir , Posaconazole , Ritonavir , Quinupristin , Saquinavir , Tamoxifen , Telithromycin , Troleandomycin , Verapamil , Voriconazole . Inducers : Aminoglutethimide , Bexarotene , Bosentan , Carbamazepine , Efavirenz , Fosphenytoin , Griseofulvin , Modafinil , Nafcillin , Nevirapine , Oxcarbazepine , Phenobarbital , Phenytoin , Primidone , Rifabutin , Rifampin , Rifapentine , St. John 's wort , Sulfadimidine , Sulfinpyrazone , Troglitazone , Troleandomycin . All concomitant medication must record . Patients also must agree refrain drinking grapefruit juice study . Sexually Active Patients : For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Patients must sign approve informed consent . More 3 prior chemotherapy treatment metastatic disease . Patients receive antiretroviral therapy ( HAART ) HIV infection possible pharmacokinetic interaction . Active CNS disease Any serious medical psychiatric illness would prevent either give informed consent receipt treatment . Patients pregnant nursing . Patients use tobacco nicotine product contain medication within last three month give significant effect erlotinib drug level .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>TNBC</keyword>
</DOC>